Jacques Descotes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11971950/publications.pdf

Version: 2024-02-01

201674 214800 2,270 62 27 47 citations h-index g-index papers 68 68 68 1998 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical Toxicity of the Interferons. Drug Safety, 1994, 10, 115-150.	3.2	238
2	Immunosuppressive drugs and cancer. Toxicology, 2003, 185, 229-240.	4.2	176
3	Clinical Toxicity of Cytokines Used As Haemopoietic Growth Factors. Drug Safety, 1995, 13, 371-406.	3.2	121
4	Immunotoxicity of monoclonal antibodies. MAbs, 2009, 1, 104-111.	5.2	119
5	Gell and Coombs's classification: is it still valid?. Toxicology, 2001, 158, 43-49.	4.2	116
6	Clinical Toxicity of Interleukin-2. Drug Safety, 1992, 7, 417-433.	3.2	88
7	Allergic adverse reactions to sulfonamides. Current Allergy and Asthma Reports, 2002, 2, 16-25.	5.3	84
8	Methods of evaluating immunotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 249-259.	3.3	70
9	Clinical immunotoxicity of therapeutic proteins. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1537-1549.	3.3	68
10	Cefaclor-Associated Serum Sickness-Like Disease: Eight Cases and Review of the Literature. Annals of Pharmacotherapy, 1992, 26, 910-914.	1.9	66
11	Critical Review of Preclinical Approaches to Evaluate the Potential of Immunosuppressive Drugs to Influence Human Neoplasia. International Journal of Toxicology, 2010, 29, 435-466.	1.2	66
12	Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in murine popliteal lymph node (PLN) test. Journal of Autoimmunity, 1992, 5, 183-197.	6.5	60
13	The Use ofln VitroSystems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. Journal of Immunotoxicology, 2005, 2, 61-83.	1.7	53
14	Anaphylaxis models in the guinea-pig. Toxicology, 1994, 93, 55-61.	4.2	51
15	Antibiotic-Associated Hepatitis: Update from 1990. Annals of Pharmacotherapy, 1997, 31, 204-220.	1.9	51
16	Immunotoxicology. Drug Safety, 2005, 28, 127-136.	3.2	48
17	Importance of immunotoxicity in safety assessment: a medical toxicologist's perspective. Toxicology Letters, 2004, 149, 103-108.	0.8	46
18	Evaluation of a Lymph Node Proliferation Assay for its Ability to Detect Pharmaceuticals with Potential to Cause Immune-Mediated Drug Reactions. Journal of Immunotoxicology, 2005, 2, 11-20.	1.7	40

#	Article	IF	CITATIONS
19	Pharmacokinetic drug interactions with macrolide antibiotics. Journal of Antimicrobial Chemotherapy, 1985, 15, 659-664.	3.0	39
20	NK-cell activity in immunotoxicity drug evaluation. Toxicology, 2003, 185, 241-250.	4.2	37
21	Responses of the Immune System to Injury. Toxicologic Pathology, 2000, 28, 479-481.	1.8	35
22	Drug allergy diagnosis in humans: possibilities and pitfalls. Toxicology, 2001, 158, 1-10.	4.2	34
23	Popliteal lymph node assay: facts and perspectives. Journal of Applied Toxicology, 2005, 25, 451-458.	2.8	33
24	Immunomodulating Agents and Hepatic Drug-Metabolizing Enzymes. Drug Metabolism Reviews, 1985, 16, 175-184.	3.6	31
25	Toxicovigilance: A new approach for the hazard identification and risk assessment of toxicants in human beings. Toxicology and Applied Pharmacology, 2005, 207, 599-603.	2.8	30
26	Sudden Death of Cardiac Origin and Psychotropic Drugs. Frontiers in Pharmacology, 2012, 3, 76.	3.5	30
27	Autoimmunity and toxicity testing. Toxicology Letters, 2000, 112-113, 461-465.	0.8	28
28	Compared effects of morphine and nickel chloride on NK cell activityin vitro in rats and monkeys. Journal of Applied Toxicology, 2001, 21, 431-434.	2.8	28
29	Ivabradine Induces an Increase in Ventricular Fibrillation Threshold During Acute Myocardial Ischemia: An Experimental Study. Journal of Cardiovascular Pharmacology, 2008, 52, 548-554.	1.9	27
30	Hidden Cardiac Lesions and Psychotropic Drugs as a Possible Cause of Sudden Death in Psychiatric Patients: A Report of 14 Cases and Review of the Literature. Canadian Journal of Psychiatry, 2004, 49, 100-105.	1.9	26
31	Clinical and histopathological progression of lesions in lupus-prone (NZB×NZW) F1 mice. Experimental and Toxicologic Pathology, 2004, 56, 37-44.	2.1	25
32	Acute Hexogen Poisoning After Occupational Exposure. Journal of Toxicology: Clinical Toxicology, 1996, 34, 109-111.	1.5	23
33	From clinical to human toxicology: linking animal research and risk assessment in man. Toxicology Letters, 2003, 140-141, 3-10.	0.8	23
34	Autoimmune diseases and vaccinations. European Journal of Dermatology, 2004, 14, 86-90.	0.6	23
35	Morphology of popliteal lymph node responses in brownâ€norway rats. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1994, 41, 95-108.	2.3	22
36	Contact sensitization assays in guinea-pigs: are they predictive of the potential for systemic allergic reactions?. Toxicology, 1994, 93, 63-75.	4.2	19

#	Article	IF	CITATIONS
37	Spiramycin: safety in man. Journal of Antimicrobial Chemotherapy, 1988, 22, 207-210.	3.0	18
38	Treatment of Drug-Induced Agranulocytosis with Haematopoietic Growth Factors. BioDrugs, 1999, 11, 185-200.	4.6	18
39	Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: Role of myocyte structure and myocardial perfusion. Resuscitation, 2011, 82, 1092-1099.	3.0	17
40	Adverse Consequences of Chemical Immunomodulation. Clinical Research Practices and Drug Regulatory Affairs, 1985, 3, 45-52.	0.0	13
41	Flu-Like Syndrome and Cytokines. Methods in Pharmacology and Toxicology, 2007, , 193-204.	0.2	12
42	Cytokine release does not improve the sensitivity and specificity of the direct popliteal lymph node assay. Toxicology, 2004, 200, 247-254.	4.2	11
43	Immunotoxicology: health aspects and regulatory issues. Trends in Pharmacological Sciences, 1986, 7, 1-3.	8.7	10
44	Trimetazidine Protective Effect Against Ischemia-Induced Susceptibility to Ventricular Fibrillation in Pigs. Cardiovascular Drugs and Therapy, 2008, 22, 29-36.	2.6	10
45	Pregnancy outcome after risk assessment of occupational exposure to organic solvents: A prospective cohort study. Reproductive Toxicology, 2010, 30, 409-413.	2.9	10
46	Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status. Resuscitation, 2013, 84, 384-390.	3.0	10
47	Occupational toxic risks in dental laboratory technicians. Journal of Environmental Medicine, 1999, 1, 307-314.	0.2	9
48	Popliteal lymph node responses to acetone and ethanol differ from those induced by streptozotocin. Archives of Toxicology, 2004, 78, 649-654.	4.2	8
49	Role of natural killer cells in immunotoxicity: an update. Expert Review of Clinical Immunology, 2005, 1, 603-608.	3.0	7
50	The effects of ropivacaine at clinically relevant doses on myocardial ischemia in pigs. Journal of Anesthesia, 2006, 20, 341-343.	1.7	7
51	Lymphocyte activation by liposome-trapped streptozotocin in murine popliteal lymph node (PLN) test. International Journal of Immunopharmacology, 1994, 16, 817-824.	1.1	6
52	Clinical Adverse Effects of Cytokines on the Immune System. Methods in Pharmacology and Toxicology, 2007, , 319-348.	0.2	5
53	Chemical Structure and Safety of Spiramycin. Drug Investigation, 1993, 6, 43-48.	0.6	4
54	Acute Occupational Poisoning By Octogen: First Case Report. Clinical Toxicology, 2006, 44, 189-190.	1.9	4

#	Article	IF	CITATIONS
55	Translational immunologic safety evaluation: A perspective. Journal of Immunotoxicology, 2013, 10, 83-89.	1.7	2
56	Drugs acting on the immune system. Side Effects of Drugs Annual, 1995, , 334-368.	0.6	1
57	Use of Contact Hypersensitivity in Immunotoxicity Testing. Methods in Molecular Biology, 2010, 598, 233-239.	0.9	1
58	A9 Immune response in human pathology: Hypersensitivity and autoimmunity., 2011,, 139-149.		1
59	Immunomodulating agents. Side Effects of Drugs Annual, 1993, 17, 432-435.	0.6	O
60	Immune response in human pathology: hypersensitivity and autoimmunity., 2005, , 117-127.		0
61	Safety Assessment Studies: Immunotoxicity. , 0, , 269-321.		O
62	Target Sites. , 2009, , 451-455.		0